214 related articles for article (PubMed ID: 28391422)
1. Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.
Harrison DJ; Schwartz CL
Curr Treat Options Oncol; 2017 Apr; 18(4):24. PubMed ID: 28391422
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy in Nonmetastatic Osteosarcoma: Recent Advances and Implications for Developing Countries.
Rastogi S; Aggarwal A; Tiwari A; Sharma V
J Glob Oncol; 2018 Sep; 4():1-5. PubMed ID: 30241154
[TBL] [Abstract][Full Text] [Related]
3. Future Directions in the Treatment of Osteosarcoma.
Smrke A; Anderson PM; Gulia A; Gennatas S; Huang PH; Jones RL
Cells; 2021 Jan; 10(1):. PubMed ID: 33467756
[TBL] [Abstract][Full Text] [Related]
4. Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial).
Barnes DJ; Dutton P; Bruland Ø; Gelderblom H; Faleti A; Bühnemann C; van Maldegem A; Johnson H; Poulton L; Love S; Tiemeier G; van Beelen E; Herbschleb K; Haddon C; Billingham L; Bradley K; Ferrari S; Palmerini E; Picci P; Dirksen U; Strauss SJ; Hogendoorn PCW; Buddingh E; Blay JY; Cleton-Jansen AM; Hassan AB
BMC Cancer; 2022 Jun; 22(1):629. PubMed ID: 35672690
[TBL] [Abstract][Full Text] [Related]
5. Intensive Multimodal Therapy Combined With Long-term Temozolomide and Etoposide Treatment for Recurrent Osteosarcoma to the Liver and Stomach.
Umeda K; Taura K; Kato I; Saida S; Hiramatsu H; Shimizu H; Nakamoto Y; Uto M; Mizowaki T; Sakamoto A; Adachi S; Okamoto T; Takita J
J Pediatr Hematol Oncol; 2022 May; 44(4):175-177. PubMed ID: 35091520
[TBL] [Abstract][Full Text] [Related]
6. Muramyl Tripeptide Plus Chemotherapy Reduces Metastasis in Non-Metastatic Osteosarcoma: A Single-Center Experience.
Taçyıldız N; Unal E; Dinçaslan H; Çakmak HM; Köse K; Tanyıldız G; Kartal Ö
Asian Pac J Cancer Prev; 2020 Mar; 21(3):715-720. PubMed ID: 32212798
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy in primary osteogenic sarcoma in patients over the age of forty.
Ozkurt B; Basarir K; Yalcin B; Merter A; Yildiz Y; Saglik Y
Acta Orthop Traumatol Turc; 2017 Mar; 51(2):123-127. PubMed ID: 28214261
[TBL] [Abstract][Full Text] [Related]
8. Systemic Cisplatin Does Not Affect the Bone Regeneration Process in a Critical Size Defect Murine Model.
Brozovich AA; Lenna S; Brenner C; Serpelloni S; Paradiso F; McCulloch P; Yustein JT; Weiner B; Taraballi F
ACS Biomater Sci Eng; 2024 Mar; 10(3):1646-1660. PubMed ID: 38350651
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for Bone and Soft Tissue Sarcomas.
Uehara T; Fujiwara T; Takeda K; Kunisada T; Ozaki T; Udono H
Biomed Res Int; 2015; 2015():820813. PubMed ID: 26167500
[TBL] [Abstract][Full Text] [Related]
10. Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.
Rivera-Valentin RK; Zhu L; Hughes DP
Paediatr Drugs; 2015 Aug; 17(4):257-71. PubMed ID: 26002157
[TBL] [Abstract][Full Text] [Related]
11. The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive.
Kast RE
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895152
[TBL] [Abstract][Full Text] [Related]
12. Research Progress of Nanomaterials in Chemotherapy of Osteosarcoma.
Yu T; Cai Z; Chang X; Xing C; White S; Guo X; Jin J
Orthop Surg; 2023 Sep; 15(9):2244-2259. PubMed ID: 37403654
[TBL] [Abstract][Full Text] [Related]
13. The Targeted Therapies for Osteosarcoma
Wang S; Ren Q; Li G; Zhao X; Zhao X; Zhang Z
Curr Mol Pharmacol; 2024; 17(1):e210823220109. PubMed ID: 37602543
[TBL] [Abstract][Full Text] [Related]
14. The generation and use of animal models of osteosarcoma in cancer research.
Pu F; Guo H; Shi D; Chen F; Peng Y; Huang X; Liu J; Zhang Z; Shao Z
Genes Dis; 2024 Mar; 11(2):664-674. PubMed ID: 37692517
[TBL] [Abstract][Full Text] [Related]
15. Blockade of IL-10 Signaling Ensures Mifamurtide Efficacy in Metastatic Osteosarcoma.
Nastasi N; Pasha A; Bruno G; Subbiani A; Pietrovito L; Leo A; Scala L; de Simone L; Casazza G; Lunardi F; Taddei ML; Tamburini A; Tondo A; Favre C; Calvani M
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835437
[TBL] [Abstract][Full Text] [Related]
16. Controversies and Challenges in the Management of Osteosarcoma-an Indian Perspective.
Mittal A; Pushpam D; Ganguly S; Kumar VS; Khan SA; Bakhshi S
Indian J Surg Oncol; 2022 Dec; 13(4):939-955. PubMed ID: 36687236
[TBL] [Abstract][Full Text] [Related]
17. The molecular pathogenesis of osteosarcoma: a review.
Broadhead ML; Clark JC; Myers DE; Dass CR; Choong PF
Sarcoma; 2011; 2011():959248. PubMed ID: 21559216
[TBL] [Abstract][Full Text] [Related]
18. Recent Insights into Therapy Resistance in Osteosarcoma.
Prudowsky ZD; Yustein JT
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396725
[TBL] [Abstract][Full Text] [Related]
19. Current and future therapeutic approaches for osteosarcoma.
Harrison DJ; Geller DS; Gill JD; Lewis VO; Gorlick R
Expert Rev Anticancer Ther; 2018 Jan; 18(1):39-50. PubMed ID: 29210294
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
